A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

To evaluate safety and determine the recommended Phase II dose (RP2D). We hypothesize that targeting leukemia stem/progenitor cells (LSCs) with nadunolimab (IL1RAP antibody) alone or in combination with current therapies of azacitidine (HMA) and venetoclax (Bcl-2 inhibitor), is an effective treatment strategy for high-risk MDS and AML, and with a clinical trial we will establish the safety and the early efficacy of this approach.

开始日期2025-01-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT05181462 / Recruiting临床1/2期

A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer. "TRIFOUR Study"

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) worldwide. The term triple negative means that tumor growth is not stimulated by the hormones estrogen and progesterone, nor by the HER2 protein, so unlike other types of BC, TNBC, which is an aggressive form of BC, does not have specific effective therapies available being the least common form of BC and the most difficult to treat.
Advanced or metastatic TNBC is treated with combinations of platinum-based chemotherapy with taxanes or gemcitabine with a 5-year survival rate of 12%. Recent studies have shown that TNBC expresses Interleukin 1 Receptor Accessory Protein (IL1RAP) at higher levels than other forms of BC.
Nadunolimab is a fully humanized monoclonal antibody that blocks the signals that occur within the cell produced by IL1RAP protein, thereby impairing the cancer cells' ability to secrete tumor stimulating substances, in turn reducing the tumor, inflammation and tumor progression. On the other hand, it is an antibody designed to activate the immune system to fight cancer cells.
This clinical trial is divided into two phases, phase Ib in which it is expected to include up to 15 patients and phase II in which it is expected to include 102 patients. The main purpose of phase Ib is to ensure that the combination of nadunolimab plus chemotherapy (gemcitabine plus carboplatin) is safe and determine the highest dose of nadunolimab that can be given safely without causing serious side effects. If the pre-specified objectives in this part are achieved, the trial will be expanded to a randomized phase II, to evaluate the efficacy of the combination of nadunolimab plus gemcitabine plus carboplatin, compared to a control group that will receive gemcitabine plus carboplatin only.

开始日期2022-01-11

申办/合作机构

Cantargia AB

[+1]

EUCTR2021-001695-42-ES / Unknown status临床1/2期

A Phase 1/2 study of CAN04, a fully humanised monoclonal antibody against IL1RAP, in combination with different chemotherapy regimens in subjects with advanced solid tumours

开始日期2021-09-22

申办/合作机构

Cantargia AB

100 项与尼达利单抗相关的临床结果

登录后查看更多信息

100 项与尼达利单抗相关的转化医学

登录后查看更多信息

100 项与尼达利单抗相关的专利（医药）

登录后查看更多信息

项与尼达利单抗相关的文献（医药）

2024-12-02·CLINICAL CANCER RESEARCH

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

Article

作者: Zvirbule, Zanete ; Sanfridson, Annika ; Awada, Ahmad ; Eefsen, Rikke L. ; Yachnin, Jeffrey ; Ochsenreither, Sebastian ; Rydberg Millrud, Camilla ; Magnusson, Susanne ; Tersago, Dominique ; Arnold, Dirk ; Collignon, Joelle ; Baltruskeviciene, Edita ; Ivanauskas, Audrius ; Garcia-Ribas, Ignacio ; Pfeiffer, Per ; Losic, Nedjad ; Van Cutsem, Eric

Abstract:

Purpose::

IL1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab is an IL1 receptor accessory protein (IL1RAP)–targeting antibody with enhanced antibody-dependent cellular cytotoxicity that blocks IL1α/IL1β signaling. We investigated efficacy and safety of nadunolimab in PDAC, in combination with gemcitabine/nab-paclitaxel (GN).

Patients and Methods::

Patients with previously untreated locally advanced/metastatic PDAC received nadunolimab (1.0–7.5 mg/kg) every 2 weeks with standard GN. The primary objective was safety; secondary objectives were antitumor response, progression-free survival, and overall survival (OS). Correlations between serum and tumor biomarkers and clinical response were explored.

Results::

Seventy-six patients were enrolled; the median age was 63 years (range, 43–89), 42% were female, 97% had metastatic disease, and 9% had received adjuvant chemotherapy. The most frequent grade ≥3 adverse event was neutropenia (66%), typically during cycle 1. Infusion-related reactions occurred in 29% (grade 3, 3%). Only 1 of the 76 patients had grade 3 or above peripheral neuropathy. No marked dose-dependent differences in safety or efficacy were observed among the four dose groups. The median OS was 13.2 months (95% confidence interval, 11.0–15.6), and the 1-year survival rate was 58%. The median immune PFS (immune Response Evaluation Criteria in Solid Tumours) was 7.1 months (95% confidence interval, 5.2–7.4). Treatment efficacy was higher in patients with high versus low tumor baseline IL1RAP expression (OS 14.2 vs. 10.6 months; P = 0.012). A reduction in serum IL8 on treatment correlated with prolonged OS.

Conclusions::

Nadunolimab combined with GN shows promising efficacy and manageable safety in locally advanced/metastatic PDAC. Higher tumor baseline IL1RAP expression correlated with better outcome.

2023-03-01·Cancer immunology, immunotherapy : CII

Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy

Article

作者: Rydberg Millrud, Camilla ; von Wachenfeldt, Karin ; Deronic, Adnan ; Grönberg, Caitríona ; Liberg, David ; Forsberg, Göran ; Jaensson Gyllenbäck, Elin

IL-1α and IL-1β are both involved in several aspects of tumor biology, including tumor initiation, progression, metastasis, and not least in resistance to various therapies. IL-1α can function as an alarmin to signal cellular stress, and acts to induce downstream events, including production of IL-1β, to amplify the signal. Both IL-1α and IL-1β act through the same receptor complex, IL-1R1-IL1RAP, to mediate signal transduction. IL1RAP is expressed on tumor cells and in the tumor microenvironment by for example CAF, macrophages and endothelial cells. The anti-IL1RAP antibody nadunolimab (CAN04) inhibits both IL-1α and IL-1β signaling and induces ADCC of IL1RAP-expressing tumor cells. As both IL-1α and IL-1β mediate chemoresistance, the aim of this study was to explore the potential synergy between nadunolimab and chemotherapy. This was performed using the NSCLC PDX model LU2503 and the syngeneic MC38 model, in addition to in vitro cell line experiments. We show that chemotherapy induces expression and release of IL-1α from tumor cells and production of IL-1β-converting enzyme, ICE, in the tumor stroma. IL-1α is also demonstrated to act on stromal cells to further induce the secretion of IL-1β, an effect disrupted by nadunolimab. Nadunolimab, and its surrogate antibody, synergize with platinum-based as well as non-platinum-based chemotherapy to induce potent anti-tumor effects, while blockade of only IL-1β signaling by anti-IL-1β antibody does not achieve this effect. In conclusion, blockade of IL1RAP with nadunolimab reduces IL-1-induced chemoresistance of tumors.

2022-04-01·British journal of cancer1区 · 医学

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

1区 · 医学

Article

作者: Eskens, Ferry ; Thorsson, Lars ; Steeghs, Neeltje ; Guren, Tormod Kyrre ; Jungels, Christiane ; Spanggaard, Iben ; Robbrecht, Debbie ; Fretland, Signe Ø ; Liberg, David ; Svedman, Christer ; Sorensen, Morten Mau ; Awada, Ahmad ; Aftimos, Philippe

BACKGROUND:

Interleukin-1 (IL-1) signalling is involved in various protumoural processes including proliferation, immune evasion, metastasis and chemoresistance. CAN04 is a first-in-class monoclonal antibody that binds IL-1 receptor accessory protein (IL1RAP), required for IL-1 signalling. In this first-in-human phase 1 study, we assessed safety, recommended phase 2 dose (RP2D), pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of CAN04 monotherapy.

METHODS:

Patients with advanced solid tumours known to express IL1RAP and refractory to standard treatments were enrolled in a dose-escalation study with 5 dose levels (1.0-10.0 mg/kg) of weekly CAN04.

RESULTS:

Twenty-two patients were enrolled. Most common adverse events were infusion-related reactions (41%), fatigue (32%), constipation (27%), diarrhoea (27%), decreased appetite (23%), nausea (23%) and vomiting (23%). One dose limiting toxicity was reported. No maximum tolerated dose was identified. Pharmacokinetics analyses indicate higher exposures and slower elimination with increasing doses. Decreases in serum IL-6 and CRP were observed in most patients. Twenty-one patients were evaluable for response, 43% had stable disease per immune-related response criteria with no partial/complete responses.

CONCLUSIONS:

The IL1RAP targeting antibody CAN04 can be safely administered to patients up to 10.0 mg/kg weekly, which was defined as the RP2D. Serum biomarkers supported target engagement and IL-1 pathway inhibition.

CLINICAL TRIAL REGISTRATION:

NCT03267316.

项与尼达利单抗相关的新闻（医药）

2024-12-11

·access wire

Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational Results on Nadunolimab Treatment in Advanced Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

LUND, SWEDEN / ACCESSWIRE / December 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported updated results from the phase 1b study in 15 advanced triple negative breast cancer (aTNBC) patients treated with nadunolimab combined with platinum-based chemotherapy. The results confirm previous positive findings on safety, and promising antitumor activity. The clinical results along with new biomarker studies will be presented in a poster session at the upcoming San Antonio Breast Cancer Symposium (SABCS), 2024."Besides the strong clinical results already reported in pancreatic and lung cancers, we are excited to present these data in triple negative breast cancer. The presentation includes value-adding information around nadunolimab and its potential effects on the immune system's ability to counteract cancer progression," said Göran Forsberg, CEO of Cantargia.The TRIFOUR phase 1b part evaluated nadunolimab at 1 mg/kg (n=3) and 2.5 mg/kg (n=12) combined with gemcitabine and carboplatin (GC) in 15 previously treated aTNBC patients. Initial results were presented in 2023, and the updated results confirm an acceptable safety profile with a promising efficacy of 60% response rate, 6.2 months progression-free survival (PFS), and 12.8 months overall survival (OS).Analysis of patient samples was performed to identify features connected to nadunolimab/GC treatment. A significant reduction in the neutrophil to lymphocyte ratio (NLR) and C-reactive protein (CRP) was detected, both related to the nadunolimab mode of action. Additionally, a significant decrease in IL-8 levels was associated with a trend towards longer OS. These findings suggest that nadunolimab exerts beneficial effects on immune cells involved in tumor-promoting inflammation.Using a larger, separate set of pre-treatment tumor biopsies and blood samples, a characterization of IL1RAP expression was also performed. This analysis showed IL1RAP expression on tumor, stromal and tumor-infiltrating immune cells. Detailed analysis of circulating cells showed IL1RAP expression on myeloid cells, including myeloid-derived suppressor cells highlighting the relevance of IL1RAP as a promising target in aTNBC.The trial is currently enrolling patients for the randomized phase 2 part at the 2.5 mg/kg dose of nadunolimab with GC vs. only GC. Initial results for this part of the study are expected late H1 2025.The study is done in collaboration with GEICAM (Spanish Breast Cancer Research Group) and will be presented in a poster session at the 47th annual San Antonio Breast Cancer symposium (SABCS), Dec 10-13, 2024.More information on the poster session is found below:Poster number: SESS-3615Poster title: Updated safety, efficacy and emerging biomarker data from the Phase Ib part of a Phase Ib/II clinical study of nadunolimab in combination with gemcitabine and carboplatin in patients with advanced triple negative breast cancer (TRIFOUR study)Session date and time: December 11, 2024 (12:30 - 2:00 PM CST)The poster will be presented at the SABCS, 2024 in San-Antonio, Texas on Dec 11 from 12:30 - 2:00 PM local time by Dr Marta Santisteban Eslava, member of the GEICAM working group for triple negative disease, and one of the Chief Investigators of the TRIFOUR study. The poster related to the presentation will be uploaded on Cantargia's webpage www.cantargia.com.For further information, please contactGöran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: [email protected]About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.About nadunolimab (CAN04)The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316, evaluates nadunolimab in combination with standard chemotherapies in patients with PDAC (gemcitabine/nab-paclitaxel) or NSCLC (platinum-based chemotherapies). Positive data show durable responses for the combination therapy in 73 PDAC patients, resulting in median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 40 NSCLC patients with median PFS of 7.2 months and a response rate of 55%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase Ib/II trial TRIFOUR, NCT05181462, also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine.About GEICAMGEICAM is the leader group in breast cancer research in Spain with a recognized worldwide prestige. It is formed by more than 900 experts, who work in 200 institutions throughout Spain.Since its establishment in 1995 until now GEICAM has performed more than a hundred of studies in which almost 68,000 women and men have participated.It has a large multidisciplinary team specialized in the management of clinical trials and other studies, which collaborates with clinical researchers in the design and implementation of clinical trials, as well as in their execution and dissemination in forums and high-impact scientific journals.For more information, you can visit the official website http://www.geicam.org or follow GEICAM on Twitter @GEICAM, @GEICAMujer, and on Facebook.com/GEICAM.AttachmentsCantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer SymposiumSOURCE: Cantargia

临床1期临床结果临床2期

2024-12-02

·access wire

Extraordinary General Meeting in Cantargia AB (publ)

LUND, SE / ACCESSWIRE / December 02, 2024 / Cantargia (STO:CANTA) Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase the company's share capital through the issuance of new shares with pre-emptive rights for the company's shareholders. Subscription may also be made without pre-emptive rights, as set forth in the complete issue resolution.Through the rights issue, Cantargia's share capital will increase with not more than SEK 7,347,467.36, through the issue of not more than 91,843,342 new shares.The record date for the right to participate in the rights issue is December 4, 2024. Two existing shares held on the record date, entitle to subscription for one new share. The subscription price is SEK 1.85 per share.For further details and information about the background and reasons for the rights issue, see Cantargia's press release on November 6, 2024.For further information, please contactGöran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: [email protected]About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com .AttachmentsExtraordinary general meeting in Cantargia AB (publ)SOURCE: Cantargia

抗体药物偶联物

2024-11-29

·access wire

Cantargia Expands the CAN10 Phase 1 Clinical Program Building on Positive Results

LUND, SWEDEN / ACCESSWIRE / November 29, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study to investigate higher dose levels of the antibody. The purpose of this expansion is to build on the good safety, potent effects on biomarkers and pharmacokinetic properties of CAN10. Current data indicate durable effects and potential for treatment every 4th week, which will be a competitive advantage. The first participant in this program has now been dosed." The accrued CAN10 clinical results underscore the potential for dosing every 4th week. This is a competitive advantage, therefore the ongoing phase 1 clinical trial is expanded to obtain additional results before the planned start of phase 2 during H2 2025 ", said Göran Forsberg, CEO of Cantargia.CAN10 is an antibody against IL1RAP, designed to potently inhibit the activity of the pro-inflammatory and disease promoting cytokines IL-1, IL-33 and IL-36. CAN10 is currently examined in a phase 1 clinical trial with the primary goal to investigate safety. So far, healthy participants have been treated in 9 single ascending dose (SAD) cohorts and the first multiple ascending dose (MAD) cohort in participants with mild to moderate plaque psoriasis is ongoing. No safety concerns have been reported and biomarker studies confirm binding to immune cells like neutrophils and monocytes as well as complete inhibition of IL-1 and IL-36 stimulation.The results obtained indicate that CAN10 has long-lasting effects that would allow dosing every 4th week, while several other antibodies use more frequent dosing. To further document this potential competitive advantage e.g. leading to improved patient convenience, the clinical protocol has been amended to allow up to two additional SAD cohorts as well as up to two additional MAD cohorts in healthy participants. The first participant in this new part of the trial has been dosed. The plan is to perform these activities during the upcoming months in line with the plan to start phase 2 during H2 2025.For further information, please contactGöran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: [email protected]This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-29 13:25 CET.About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com .About CAN10The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. The initial focus of CAN10 will be on two severe diseases: hidradenitis suppurativa (HS) and systemic sclerosis. In preclinical in vivo models of inflammatory diseases, such as systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, myocarditis and peritonitis, a CAN10 surrogate antibody significantly reduced the development of the disease. A clinical phase 1 study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing. Good safety is shown at the completed dose levels, and additional data are expected continuously during 2025.AttachmentsCantargia expands the CAN10 phase 1 clinical program building on positive resultsSOURCE: Cantargia

临床1期临床结果抗体药物偶联物

100 项与尼达利单抗相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床2期	美国	Cantargia AB	2024-02-20
晚期三阴性乳腺癌	临床2期	西班牙	Cantargia AB	2022-01-11
晚期恶性实体瘤	临床2期	法国	Cantargia AB	2021-09-22
晚期恶性实体瘤	临床2期	西班牙	Cantargia AB	2021-09-22
胆道癌	临床2期	法国	Cantargia AB	2021-09-22
胆道癌	临床2期	西班牙	Cantargia AB	2021-09-22
非小细胞肺癌	临床2期	法国	Cantargia AB	2021-09-22
结直肠癌	临床2期	奥地利	Cantargia AB	2017-09-19
结直肠癌	临床2期	比利时	Cantargia AB	2017-09-19
结直肠癌	临床2期	丹麦	Cantargia AB	2017-09-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05116891 (CESTAFOUR, Company_Website) 人工标引	临床1/2期	肿瘤 \| 非小细胞肺癌 \| 胆道癌	-	Nadunolimab in combination with gemcitabine/cisplatin (NSCLC + first arm)	繭選簾糧壓顧衊廠鑰願(積鬱淵構遞蓋膚網夢鏇) = 繭觸壓憲鏇糧餘積壓範醖廠鏇醖積繭糧觸憲齋 (選構鑰簾築獵鹹鬱襯鬱 ) 更多	积极	2024-10-28
				Nadunolimab in combination with gemcitabine/cisplatin (biliary tract cancer + first arm)	繭選簾糧壓顧衊廠鑰願(積鬱淵構遞蓋膚網夢鏇) = 鹹鏇構鑰鬱齋鹹衊鏇窪醖廠鏇醖積繭糧觸憲齋 (選構鑰簾築獵鹹鬱襯鬱 ) 更多
NCT05116891 (CANFOUR, ESMO2024) 人工标引	临床1/2期	非小细胞肺癌一线 \| 二线	40	Nadunolimab cisplatingemcitabine	(糧艱廠蓋廠淵範衊積襯) = 築願襯積觸衊憲鏇鹽壓餘觸鏇繭廠積襯衊鑰積 (蓋膚憲壓築獵簾夢網廠 ) 更多	积极	2024-09-14
				Nadunolimab cisplatingemcitabine	(糧艱廠蓋廠淵範衊積襯) = 願餘糧積築鑰觸膚網網餘觸鏇繭廠積襯衊鑰積 (蓋膚憲壓築獵簾夢網廠 ) 更多
NCT05181462 (TRIFOUR, ESMO2023) 人工标引	临床1/2期	三阴性乳腺癌 HER2 Negative \| ER Negative \| PR Negative	13	nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 1 mg/kg)	醖鑰選遞製構鏇餘糧築(廠觸網衊顧壓鹹膚餘鏇) = 範範膚網窪淵夢觸膚鹽築艱醖鏇繭選顧憲蓋艱 (願顧壓膚蓋鹹製築廠網 )	积极	2023-10-21
				nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 2.5 mg/kg)	醖鑰選遞製構鏇餘糧築(廠觸網衊顧壓鹹膚餘鏇) = 繭網齋襯製鬱蓋觸夢襯築艱醖鏇繭選顧憲蓋艱 (願顧壓膚蓋鹹製築廠網 )
CANFOUR (AACR2023)	临床1/2期	胰腺导管腺癌	73	Nadunolimab	範網範鹹齋鑰衊範網觸(遞窪製廠鹽淵網顧鹹夢) = 鏇壓蓋觸淵襯範壓窪淵襯襯獵衊積遞簾窪憲鏇 (簾夢鹹築窪範膚顧餘築, 10.0 ~ 19.1) 更多	-	2023-04-04